结直肠腺癌分级:AJCC与WHO标准的观察者间一致性及诊断挑战再审视
五名胃肠病理学家对100张结直肠腺癌扫描切片分别按WHO第5版、WHO第6版、AJCC第8版及临床实践进行分级。WHO6与两级AJCC8的Fleiss多评估者kappa相似(0.730 vs 0.731,P<0.001),均高于WHO5(0.655,P<0.001);WHO6和WHO5判为高级别的肿瘤数显著多于AJCC8(平均34.4和33.6 vs 11.8例,P<0.01)。
要点
- WHO6与两级AJCC8观察者间一致性相似且高于WHO5,均达显著一致水平。
- 使用WHO标准判为高级别的肿瘤数显著多于AJCC8,可能影响治疗决策。
- 病理学家对浸润前肿瘤出芽等情形一致,但对富间质区域评估存在分歧。
核心结论
- WHO6较WHO5改善了观察者间一致性,但WHO标准持续将更多肿瘤升级为高级别,可能影响治疗算法。
- 同步分级标准并在前瞻性研究中以临床结局验证至关重要。
研究设计与样本
- 五名胃肠病理学家回顾100张结直肠腺癌扫描切片,分别按WHO5、WHO6、AJCC8及临床实践分级,并进行问卷调查。
主要发现
- WHO6的Fleiss多评估者kappa为0.730(P<0.001),两级AJCC8为0.731(P<0.001),WHO5为0.655(P<0.001)。
- WHO6和WHO5判为高级别的肿瘤数平均分别为34.4例和33.6例,显著多于AJCC8的11.8例(P<0.01)。
- 所有评估者对某些情形一致(如按WHO分级时不计浸润前肿瘤出芽),但对富间质区域评估等情形存在分歧。
关键数值与推荐
- AJCC8基于腺体形成百分比分级;WHO5和WHO6基于最低分化成分分级。
- WHO6规定最低分化成分需距浸润前缘至少0.196 mm²面积方可诊断为高级别。
临床怎么用
- 病理科医生采用WHO标准分级时需注意其较AJCC8更易将肿瘤判为高级别,可能影响临床治疗决策。
- 对富间质区域等分歧场景需加强培训与共识。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Significantly more colorectal adenocarcinoma (CRC) cases were graded as high-grade via WHO 5th ed (blue bars) and WHO 6th ed (orange bars) grading criteria per reviewer, as compared to the current American Joint Committee on Cancer (AJCC) 8th ed (red bars) grading criteria. Aim The current American Joint Committee on Cancer (AJCC8) manual grades colorectal adenocarcinoma (CRC) based on the percentage of gland formation. The World Health Organization 5th ed (WHO5) and 6th ed (WHO6) grade based on the least differentiated component; WHO6 specifies a minimum 0.196 mm2 area of the least-differentiated component away from the invasive front to merit a high-grade diagnosis. We studied the interobserver agreement and challenges among pathologists when grading CRC using the above grading systems. Methods and results Five gastrointestinal pathologists reviewed 100 scanned CRC slides and graded each slide per the provided criteria in (a) WHO5, (b) WHO6, (c) AJCC8 and (d) their clinical practice. A post-survey questionnaire was also provided. The Fleiss multirater kappa among the five reviewers was similar using WHO6 (0.730, P < 0.001) and two-tiered (low vs. high) AJCC8 (0.731, P < 0.001) and was higher than WHO5 (0.655, P < 0.001) grading criteria; the agreement was substantial for all 3 grading systems. Significantly more tumours were called high-grade when using WHO6 (average: 34.4 cases) and WHO5 (average: 33.6 cases) as compared to AJCC8 (average: 11.8 cases) grading criteria (P < 0.01). All reviewers were unanimous in handling certain scenarios (e.g. discounting invasive front tumour buds with WHO grading), but were discordant on certain scenarios (e.g. assessment of stroma-rich areas). Conclusions While inter-observer agreement improved with WHO6 versus WHO5, the persistent upgrading of tumours using the WHO scheme may affect treatment algorithms. Synchronization of grading criteria with validation in prospective studies with clinical outcomes is crucial.
引用
- Histopathology:Grading colorectal adenocarcinoma: interobserver agreement between American Joint Committee on Cancer and World Health Organization criteria and revisiting diagnostic challenges
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。